{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:34:04Z","timestamp":1783636444018,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinre.2025.102689","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:11:30Z","timestamp":1758604290000},"page":"102689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances and future perspectives in the pharmacological treatment of Helicobacter pylori infection: Taking advantage from artificial intelligence"],"prefix":"10.1016","volume":"49","author":[{"given":"Maria Pina","family":"Dore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-2823","authenticated-orcid":false,"given":"Giovanni Mario","family":"Pes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinre.2025.102689_bib0001","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.gastro.2023.10.027","article-title":"Toward quantification of H pylori-associated gastric cancer risk: further evidence supporting development of population-based strategies for H pylori eradication","volume":"166","author":"Ford","year":"2024","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.clinre.2025.102689_bib0002","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102689_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.clinre.2025.102689_bib0004","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2025.102689_bib0005","unstructured":"https:\/\/www.worldgastroenterology.org\/publications\/e-wgn\/e-wgn-expert-point-of-view-articles-collection\/management-of-helicobacter-pylori-infection-in-africa-the-challenges-and-peculiarities#:\u223c:text=pylori%20infection%20prevalence%20rates%."},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0006","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12879-018-3099-4","article-title":"The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis","volume":"18","author":"Jaka","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0007","first-page":"278","article-title":"Effectiveness of triple therapy regimens in the eradication of Helicobacter Pylori in patients with uninvestigated dyspepsia in Ekiti State, Nigeria","volume":"6","author":"Solomon","year":"2014","journal-title":"J Adv Med Med Res"},{"issue":"7","key":"10.1016\/j.clinre.2025.102689_bib0008","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41395-018-0132-6","article-title":"Correction: ACG Clinical guideline: treatment of Helicobacter pylori infection","volume":"113","author":"Chey","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut,"},{"key":"10.1016\/j.clinre.2025.102689_bib0010","unstructured":"https:\/\/www.worldgastroenterology.org\/UserFiles\/file\/guidelines\/helicobacter-pylori-english-2021.pdf. Available from: https:\/\/www.worldgastroenterology.org\/guidelines\/helicobacter-pylori."},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/pharma3010006","article-title":"Crises in antimicrobial stewardship: misuse of Clarithromycin for Helicobacter pylori therapy","volume":"3","author":"Graham","year":"2024","journal-title":"Pharmacoepidemiology"},{"issue":"2","key":"10.1016\/j.clinre.2025.102689_bib0012","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102689_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev-med-042220-020814","article-title":"Diagnosis and treatment of Helicobacter pylori infection","volume":"73","author":"Lee","year":"2022","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.clinre.2025.102689_bib0014","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial","volume":"172","author":"Graham","year":"2020","journal-title":"Ann Int Med"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13148","article-title":"Efficacy and safety of Vonoprazan in dual\/triple\/quadruple regimens both in first-line and rescue therapy for Helicobacter pylori eradication: a systematic review with meta-analysis","volume":"29","author":"Benito","year":"2024","journal-title":"Helicobacter,"},{"key":"10.1016\/j.clinre.2025.102689_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus Proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"Biomed Res Int"},{"issue":"9","key":"10.1016\/j.clinre.2025.102689_bib0017","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0018","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinre.2025.102689_bib0019","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/gutjnl-2023-329826","article-title":"Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials","volume":"73","author":"Chen","year":"2024","journal-title":"Gut"},{"issue":"10500","key":"10.1016\/j.clinre.2025.102689_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(25)00899-2","article-title":"Future direction of Helicobacter pylori infection treatment","volume":"406","author":"Graham","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0021","first-page":"665","article-title":"Use of artificial intelligence for the detection of Helicobacter pylori infection from upper gastrointestinal endoscopy images: an updated systematic review and meta-analysis","volume":"37","author":"Parkash","year":"2024","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0022","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1038\/s41467-025-61329-5","article-title":"The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations","volume":"16","author":"Higgins","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0023","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.gastro.2018.01.018","article-title":"Update on the use of Vonoprazan: a competitive acid blocker","volume":"154","author":"Graham","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2025.102689_bib0024","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10620-023-07886-5","article-title":"Why the Vonoprazan Helicobacter pylori therapies in the US-european trial produced unacceptable cure rates","volume":"68","author":"Graham","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.14309\/ajg.0000000000001659","article-title":"Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why","volume":"117","author":"Graham","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0026","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.gastro.2024.12.022","article-title":"Regarding the AGA clinical practice update on integrating Vonoprazan into clinical practice","volume":"168","author":"Graham","year":"2025","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.clinre.2025.102689_bib0027","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.clinre.2025.102689_bib0028","article-title":"A comprehensive review on the efficacy and safety of Vonoprazan in the management of gastric acid-related diseases","volume":"16","author":"Padwale","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.clinre.2025.102689_bib0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3748\/wjg.v29.i2.390","article-title":"Third-line and rescue therapy for refractory Helicobacter pylori infection: a systematic review","volume":"29","author":"de Moraes Andrade","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.43.6.1497","article-title":"Rifampin and rifabutin resistance mechanism in Helicobacter pylori","volume":"43","author":"Heep","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2025.102689_bib0031","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000191204","article-title":"Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori","volume":"79","author":"Suzuki","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.clinre.2025.102689_bib0033","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinre.2025.102689_bib0034","series-title":"The pharmacological basis of therapeutics","author":"Gilman's","year":"2018"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter Pylori infection: a review","volume":"10","author":"Gisbert","year":"2020","journal-title":"Pathogens"},{"issue":"7","key":"10.1016\/j.clinre.2025.102689_bib0036","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in mycobacterium tuberculosis","volume":"42","author":"Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.clinre.2025.102689_bib0037","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.mayocp.2018.12.011","article-title":"Pharmacotherapy approaches in nontuberculous mycobacteria infections","volume":"94","author":"Shulha","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.clinre.2025.102689_bib0038","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11938-002-0060-8","article-title":"Rescue Therapy for Helicobacter pylori","volume":"5","author":"Leung","year":"2002","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0039","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2036.2000.00719.x","article-title":"Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens","volume":"14","author":"Perri","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","article-title":"Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori","volume":"19","author":"Lim","year":"2014","journal-title":"Helicobacter,"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0041","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/2050640615618043","article-title":"Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study","volume":"4","author":"Mori","year":"2016","journal-title":"United Euro Gastroenterol J"},{"issue":"9028","key":"10.1016\/j.clinre.2025.102689_bib0042","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(05)65109-4","article-title":"Severe neutropenia caused by recommended prophylactic doses of rifabutin","volume":"348","author":"Apseloff","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0043","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jgh.15294","article-title":"Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"36","author":"Gingold-Belfer","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061658","article-title":"Experience with Rifabutin-containing therapy in 500 patients from the European Registry on Helicobacter pylori management (Hp-EuReg)","volume":"11","author":"Nyssen","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MOG.0000000000000981","article-title":"Controversies regarding management of Helicobacter pylori infections","volume":"39","author":"Price","year":"2023","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0046","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1523-5378.2011.00857.x","article-title":"Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days","volume":"16","author":"Dore","year":"2011","journal-title":"Helicobacter,"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0047","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0048","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2016.1178065","article-title":"Helicobacter pylori therapy: a paradigm shift","volume":"14","author":"Graham","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"10.1016\/j.clinre.2025.102689_bib0049","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","article-title":"Role of bismuth in improving Helicobacter pylori eradication with triple therapy","volume":"65","author":"Dore","year":"2016","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2025.102689_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.11.s1.13.x","article-title":"The actions of bismuth in the treatment of Helicobacter pylori infection","volume":"11","author":"Lambert","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.clinre.2025.102689_bib0051","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14787210.2018.1511427","article-title":"Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies","volume":"16","author":"Graham","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12936","article-title":"Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis","volume":"28","author":"Rokkas","year":"2023","journal-title":"Helicobacter,"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0053","first-page":"159","article-title":"Best practices for Helicobacter pylori management","volume":"20","author":"Graham","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"10.1016\/j.clinre.2025.102689_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020681","article-title":"A simplified low-dose 10-day quadruple therapy with a galenic formulation of bismuth salicylate is highly effective for Helicobacter pylori eradication","volume":"12","author":"Dore","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.clinre.2025.102689_bib0055","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.14309\/ajg.0000000000001246","article-title":"Adverse event profile during the treatment of Helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg)","volume":"116","author":"Nyssen","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"10.1016\/j.clinre.2025.102689_bib0056","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.12998\/wjcc.v11.i20.4740","article-title":"Probiotics and autoprobiotics for treatment of Helicobacter pylori infection","volume":"11","author":"Baryshnikova","year":"2023","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0057","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4315\/0362-028X-66.1.3","article-title":"Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria","volume":"66","author":"Kim","year":"2003","journal-title":"J Food Prot"},{"issue":"3","key":"10.1016\/j.clinre.2025.102689_bib0058","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.gtc.2015.05.005","article-title":"Is there a role for probiotics in Helicobacter pylori therapy?","volume":"44","author":"Dore","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.clinre.2025.102689_bib0059","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3409820","article-title":"Role of probiotics in Helicobacter pylori eradication: lessons from a study of Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475 (Gastrus(R)) and a proton-pump inhibitor","volume":"2019","author":"Dore","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0060","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clinre.2017.04.004","article-title":"Probiotics in Helicobacter pylori eradication therapy: systematic review and network meta-analysis","volume":"41","author":"Wang","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"10.1016\/j.clinre.2025.102689_bib0061","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00228-017-2291-6","article-title":"Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis","volume":"73","author":"Feng","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0062","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/2050640615617358","article-title":"Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events","volume":"4","author":"McFarland","year":"2016","journal-title":"United Euro Gastroenterol J"},{"key":"10.1016\/j.clinre.2025.102689_bib0063","article-title":"Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"10.1016\/j.clinre.2025.102689_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111030","article-title":"The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis","volume":"9","author":"Dang","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.clinre.2025.102689_bib0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4321\/S1130-01082013000800002","article-title":"Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis","volume":"105","author":"Zheng","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.clinre.2025.102689_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104403","article-title":"Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects","volume":"147","author":"Zhang","year":"2020","journal-title":"Microb Pathog"},{"key":"10.1016\/j.clinre.2025.102689_bib0067","article-title":"Deciphering complex antibiotic resistance patterns in Helicobacter pylori through whole genome sequencing and machine learning","volume":"13","author":"Yu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0068","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40264-024-01505-6","article-title":"Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health\/medical records: a scoping review","volume":"48","author":"Golder","year":"2025","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0069","first-page":"550","article-title":"Effectiveness of mobile applications on medication adherence in adults with chronic diseases: a systematic review and meta-analysis","volume":"26","author":"Peng","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.clinre.2025.102689_bib0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12876-022-02614-1","article-title":"Application of a WeChat-based mini-app as a patient reminder in Helicobacter pylori eradication: a prospective multi-center randomized controlled study","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102689_bib0071","article-title":"Next generation sequencing for the prediction of the antibiotic resistance in Helicobacter pylori: a literature review","volume":"10","author":"Saracino","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"10.1016\/j.clinre.2025.102689_bib0072","first-page":"469","article-title":"Helicobacter pylori antimicrobial resistance and the role of next-generation sequencing","volume":"20","author":"Andrews","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:00:53Z","timestamp":1761966053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2210740125001664"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102689","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and future perspectives in the pharmacological treatment of Helicobacter pylori infection: Taking advantage from artificial intelligence","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102689"}}